---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-010580"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-02-07T23:59:59+00:00"
generated_at: "2026-05-27T00:49:45.056928+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma CFO Mark Guerin resigns; Nora Brennan named Interim CFO

## Summary
- Mark Guerin resigned as CFO effective Feb 5, 2025; receives $250K in 9 monthly installments plus $150K lump sum.
- Guerin gets $75K RSUs vesting over 2 years, accelerated vesting of all outstanding awards, option exercise extended to Feb 2026.
- Nora Brennan appointed Interim CFO effective Feb 5; compensation $42K/month through July 5, 2025.
- Brennan previously CFO at Spectrum Pharmaceuticals and TELA Bio; led TELA Bio through IPO.
- If extended after July 5, Brennan eligible for $425K salary, 115K RSUs, and target bonus up to 50% of salary.

## SEC filing metadata
- accession: 0001104659-25-010580
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/tm255838d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-010580
- JSON: https://secwatch.observer/filing/0001104659-25-010580.json
- Plain text: https://secwatch.observer/filing/0001104659-25-010580.txt

## Key facts
- Executive change
  Mark Guerin resigned as Chief Financial Officer at Traws Pharma, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm
- Executive change
  Nora Brennan was appointed as Interim Chief Financial Officer at Traws Pharma, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.